Indoco Remedies (INDOCO) Q4 24/25 earnings summary

Executive summary

• The year was marked by significant operational and financial challenges, including the launch of a new OTC subsidiary, major manufacturing upgrades, and regulatory setbacks impacting international sales.

• Investments in Warren Remedies Private Limited (WRPL) for OTC and cosmetic products led to higher costs and limited initial sales success, as anticipated.

• Planned shutdowns for manufacturing upgrades and an unexpected US FDA warning letter on the sterile plant in Goa severely disrupted supply to key markets, notably the US and Europe.

• Despite setbacks, flagship product Cyclopam delivered strong growth, and digitalization and cost control initiatives are underway.

• Recent positive regulatory developments include a successful EMA audit and partial US FDA clearance to restart some manufacturing lines.

Financial highlights

• Standalone Q4 net revenues were INR 3,411 million, down from INR 4,351 million year-over-year; full-year standalone revenues were INR 14,948 million, down from INR 17,620 million.

• Consolidated Q4 net revenues were INR 3,839 million, down from INR 4,391 million; full-year consolidated revenues were INR 16,413 million, down from INR 17,882 million.

• Standalone EBITDA margin for Q4 dropped to 1% (INR 35 million) from 13.2% (INR 574 million); full-year margin was 8.6% (INR 1,280 million) vs. 14.6% (INR 2,580 million).

• Consolidated EBITDA margin for Q4 was -0.2% (-INR 0.8 million) vs. 11.1% (INR 489 million); full-year margin was 6% (INR 993 million) vs. 13.7% (INR 2,443 million).

• Standalone net loss for FY25 was INR 87 million, compared to a net profit of INR 1,166 million in FY24; consolidated net loss was INR 779 million, compared to a net profit of INR 970 million.

Outlook and guidance

• Incremental sales from the sterile plant are expected to resume in Q2, with gradual recovery in US and European business anticipated.

• Remediation updates for the US FDA are expected to be completed by July/August, with the site ready for inspection thereafter.

• Management expects improvement in margins and a return to normalized performance from Q2 onward, with further upside as manufacturing and supply stabilize.

• Warren Remedies is expected to break even by FY27, with double-digit growth projected for its OTC business.